

Julian D Gillmore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/562347/publications.pdf>

Version: 2024-02-01

153
papers

13,700
citations

28274

55
h-index

22832

112
g-index

158
all docs

158
docs citations

158
times ranked

7678
citing authors

#	ARTICLE	IF	CITATIONS
1	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. <i>Heart</i> , 2022, 108, 474-478.	2.9	8
2	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2 "Evidence Base and Standardized Methods of Imaging. <i>Journal of Cardiac Failure</i> , 2022, 28, e1-e4.	1.7	8
3	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. <i>European Heart Journal</i> , 2022, 43, 333-341.	2.2	45
4	The role of serial ^{99m} Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 38-49.	3.0	8
5	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 8-13.	3.0	24
6	When to Suspect and How to Approach a Diagnosis of Amyloidosis. <i>American Journal of Medicine</i> , 2022, 135, S2-S8.	1.5	2
7	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 830006.	3.5	11
8	Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1646-1657.	4.7	30
9	RNA-targeting and gene editing therapies for transthyretin amyloidosis. <i>Nature Reviews Cardiology</i> , 2022, 19, 655-667.	13.7	64
10	Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1288-1303.	2.8	35
11	Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK. <i>Advances in Therapy</i> , 2022, 39, 2292-2301.	2.9	11
12	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. <i>European Heart Journal</i> , 2022, 43, 2622-2632.	2.2	27
13	Imaging-Guided Treatment for Cardiac Amyloidosis. <i>Current Cardiology Reports</i> , 2022, 24, 839-850.	2.9	13
14	Systemic embolism in amyloid transthyretin cardiomyopathy. <i>European Journal of Heart Failure</i> , 2022, 24, 1387-1396.	7.1	23
15	Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis. <i>ESC Heart Failure</i> , 2022, 9, 2978-2987.	3.1	3
16	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2022, 24, 1700-1712.	7.1	26
17	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 189-199.	5.3	113
18	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. <i>Lancet Neurology</i> , The, 2021, 20, 49-59.	10.2	93

#	ARTICLE	IF	CITATIONS
19	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. <i>Neurology and Therapy</i> , 2021, 10, 375-389.	3.2	34
20	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres. <i>Molecules</i> , 2021, 26, 1913.	3.8	5
21	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2021, 42, 1554-1568.	2.2	434
22	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <sc>W</sc>orking <sc>G</sc>roup on <sc>M</sc>yocardial and <sc>P</sc>ericardial <sc>D</sc>iseases. <i>European Journal of Heart Failure</i> , 2021, 23, 512-526.	7.1	153
23	Cardiac Magnetic Resonanceâ€Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, CIRCIMAGING121012506.	2.6	19
24	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 204.	2.7	11
25	A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 189-198.	3.0	12
26	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 493-502.	27.0	807
27	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€Evidence Base and Standardized Methods of Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e000029.	2.6	48
28	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€Diagnostic Criteria and Appropriate Utilization. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e000030.	2.6	16
29	^{99m} Tc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1304-1311.	1.2	26
30	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€evidence base and standardized methods of imaging. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1769-1774.	2.1	34
31	Clinical ApoAâ€IV amyloid is associated with fibrillogenic signal sequence. <i>Journal of Pathology</i> , 2021, 255, 311-318.	4.5	4
32	Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. <i>Cardiology Clinics</i> , 2021, 39, 389-402.	2.2	7
33	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin lightâ€chain (AL) amyloidosis. <i>British Journal of Haematology</i> , 2021, 194, 1016-1023.	2.5	3
34	Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis. <i>Neurology: Clinical Practice</i> , 2021, 11, e757-e759.	1.6	0
35	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. <i>Blood</i> , 2021, 138, 2721-2721.	1.4	5
36	Cardiac Amyloidosis: A Review of Current Imaging Techniques. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 751293.	2.4	16

#	ARTICLE	IF	CITATIONS
37	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. <i>Nature Communications</i> , 2021, 12, 7112.	12.8	13
38	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€”Diagnostic criteria and appropriate utilization. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 659-673.	2.1	97
39	Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 909-920.	5.3	136
40	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. <i>ESC Heart Failure</i> , 2020, 7, 3942-3949.	3.1	22
41	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. <i>Journal of Biological Chemistry</i> , 2020, 295, 11379-11387.	3.4	12
42	Two types of systemic amyloidosis in a single patient. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 275-276.	3.0	6
43	The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis. <i>European Journal of Haematology</i> , 2020, 105, 352-356.	2.2	10
44	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 153-162.	3.0	47
45	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 357-370.	2.6	55
46	Lysozyme amyloid: evidence for the W64R variant by proteomics in the absence of the wild type protein. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 206-207.	3.0	6
47	Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 948-957.	2.3	20
48	Karyomegalic interstitial nephritis with a novel FAN1 gene mutation and concurrent ALECT2 amyloidosis. <i>BMC Nephrology</i> , 2020, 21, 74.	1.8	6
49	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. <i>European Heart Journal</i> , 2020, 41, 1439-1447.	2.2	108
50	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2020, 136, 40-40.	1.4	1
51	The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis. <i>Blood</i> , 2020, 136, 16-17.	1.4	2
52	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 2065-2123.	2.1	230
53	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. <i>Journal of Cardiac Failure</i> , 2019, 25, 854-865.	1.7	70
54	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. <i>Journal of Cardiac Failure</i> , 2019, 25, e1-e39.	1.7	107

#	ARTICLE	IF	CITATIONS
55	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. <i>Blood</i> , 2019, 134, 2271-2280.	1.4	130
56	Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 52-53.	3.0	3
57	The UK National Amyloidosis Centre. <i>European Heart Journal</i> , 2019, 40, 1661-1664.	2.2	3
58	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2019, 140, 16-26.	1.6	288
59	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. <i>Lancet Haematology</i> , 2019, 6, e217-e228.	4.6	80
60	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. <i>Scientific Reports</i> , 2019, 9, 1388.	3.3	27
61	AB0901â€¦TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT. , 2019, , .		0
62	19â€¦Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia. , 2019, , .		0
63	21â€¦Intracardiac thrombi in cardiac amyloidosis, a common finding. , 2019, , .		0
64	Analysis of the <i>TTR</i> gene in the investigation of amyloidosis: A 25-year single UK center experience. <i>Human Mutation</i> , 2019, 40, 90-96.	2.5	29
65	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	9.6	330
66	Native T1 and Extracellular Volume in Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 810-819.	5.3	172
67	Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 823-833.	5.3	113
68	The UK Experience of Renal Transplantation in AL Amyloidosis. <i>Blood</i> , 2019, 134, 2206-2206.	1.4	0
69	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	94
70	A new staging system for cardiac transthyretin amyloidosis. <i>European Heart Journal</i> , 2018, 39, 2799-2806.	2.2	396
71	Extracellular volume with bolus-only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1677-1684.	3.4	7
72	3â€¦Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	Quantitation of ^{99m} Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 203-210.	3.0	42
74	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. <i>Journal of Biological Chemistry</i> , 2018, 293, 14192-14199.	3.4	68
75	Myocardial Edema and Prognosis in Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2919-2931.	2.8	145
76	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue—a case series and genetic exploration. <i>Rheumatology</i> , 2017, 56, 209-213.	1.9	49
77	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. <i>Sleep Medicine</i> , 2017, 32, 191-197.	1.6	5
78	Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein. <i>Kidney International Reports</i> , 2017, 2, 461-469.	0.8	25
79	Six-minute walk test (6MWT) in AL amyloidosis — baseline and 12-month follow-up after chemotherapy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 62-63.	3.0	4
80	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 72-73.	3.0	3
81	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. <i>European Heart Journal</i> , 2017, 38, 1905-1908.	2.2	144
82	Prognostic utility of the Perugini grading of ^{99m} Tc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1344-1350.	1.2	124
83	Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 229-237.	3.0	8
84	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. <i>Journal of Proteomics</i> , 2017, 165, 113-118.	2.4	14
85	Magnetic Resonance in Transthyretin Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 466-477.	2.8	290
86	Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 189-193.	3.0	17
87	001...Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. <i>Heart</i> , 2017, 103, A1-A2.	2.9	12
88	024...Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis. <i>Heart</i> , 2017, 103, A20-A21.	2.9	0
89	028...Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping. <i>Heart</i> , 2017, 103, A24-A24.	2.9	3
90	Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 162-166.	3.0	61

#	ARTICLE	IF	CITATIONS
91	A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. BMC Medical Imaging, 2017, 17, 3.	2.7	9
92	Comparison of Free Light Chain Assays. American Journal of Clinical Pathology, 2016, 146, 78-85.	0.7	8
93	Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis" Circulation, 2016, 133, e450-1.	1.6	4
94	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
95	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	210
96	Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrology Dialysis Transplantation, 2016, 33, gfw375.	0.7	18
97	A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype. European Journal of Medical Genetics, 2016, 59, 474-477.	1.3	14
98	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. Journal of Clinical Oncology, 2016, 34, 2037-2045.	1.6	60
99	Systemic amyloidosis. Lancet, The, 2016, 387, 2641-2654.	13.7	703
100	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, 126, 612-615.	1.4	334
101	A novel mechanoenzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Molecular Medicine, 2015, 7, 1337-1349.	6.9	109
102	The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal, 2015, 91, 439-448.	1.8	33
103	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2.2	310
104	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European Heart Journal, 2015, 36, 1098-1105.	2.2	129
105	Amyloid cardiomyopathy associated with a novel apolipoprotein A-I Q172P variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 252-253.	3.0	8
106	A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. Journal of Clinical Pathology, 2015, 68, 314-317.	2.0	95
107	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	7.3	146
108	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine, 2015, 373, 1106-1114.	27.0	304

#	ARTICLE	IF	CITATIONS
109	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. <i>Lancet Haematology</i> , 2015, 2, e241-e250.	4.6	105
110	Guidelines on the diagnosis and investigation of AL amyloidosis. <i>British Journal of Haematology</i> , 2015, 168, 207-218.	2.5	122
111	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. <i>Circulation</i> , 2015, 132, 1570-1579.	1.6	442
112	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). <i>Haematologica</i> , 2014, 99, 1479-1485.	3.5	118
113	Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies. <i>Journal of Clinical Pathology</i> , 2014, 67, 661-666.	2.0	11
114	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1289-1298.	1.2	184
115	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. <i>Human Mutation</i> , 2014, 35, E2403-E2412.	2.5	220
116	Native T1 Mapping in Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 157-165.	5.3	339
117	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1539-1544.	7.1	91
118	CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 133-142.	5.3	242
119	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. <i>Haematologica</i> , 2014, 99, e260-e263.	3.5	14
120	Two types of amyloid in a single heart. <i>Blood</i> , 2014, 124, 3025-3027.	1.4	24
121	Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis. <i>Blood</i> , 2014, 124, 726-726.	1.4	1
122	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2014, 124, 305-305.	1.4	0
123	Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD). <i>Blood</i> , 2014, 124, 1198-1198.	1.4	1
124	Pathophysiology and treatment of systemic amyloidosis. <i>Nature Reviews Nephrology</i> , 2013, 9, 574-586.	9.6	93
125	Structure, Folding Dynamics, and Amyloidogenesis of D76N Î²2-Microglobulin. <i>Journal of Biological Chemistry</i> , 2013, 288, 30917-30930.	3.4	80
126	Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome. <i>Journal of the American Heart Association</i> , 2013, 2, e000098.	3.7	275

#	ARTICLE	IF	CITATIONS
127	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. <i>Blood</i> , 2013, 121, 3420-3427.	1.4	385
128	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. <i>Blood</i> , 2012, 120, 2966-2966.	1.4	2
129	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. <i>Blood</i> , 2012, 120, 4074-4074.	1.4	1
130	ALchemy - A Large Prospective 'Real World' Study of Chemotherapy in AL Amyloidosis. <i>Blood</i> , 2011, 118, 992-992.	1.4	26
131	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. <i>Blood</i> , 2011, 118, 995-995.	1.4	5
132	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. <i>Blood</i> , 2011, 118, 3975-3975.	1.4	1
133	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. <i>Blood</i> , 2011, 118, 3978-3978.	1.4	1
134	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. <i>British Journal of Haematology</i> , 2010, 148, 760-767.	2.5	106
135	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2010, 116, 988-988.	1.4	25
136	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. <i>Blood</i> , 2010, 116, 3958-3958.	1.4	0
137	Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen A α -Chain Amyloidosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 444-451.	6.1	145
138	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. <i>Blood</i> , 2009, 114, 1791-1791.	1.4	4
139	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. <i>Blood</i> , 2009, 114, 2796-2796.	1.4	6
140	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis ' Results From the UK Amyloidosis Treatment Trial.. <i>Blood</i> , 2009, 114, 2869-2869.	1.4	13
141	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. <i>Blood</i> , 2009, 114, 745-745.	1.4	6
142	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. <i>Blood</i> , 2009, 114, 2814-2814.	1.4	0
143	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. <i>Blood</i> , 2009, 114, 1863-1863.	1.4	0
144	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. <i>Blood</i> , 2008, 112, 1689-1689.	1.4	7

#	ARTICLE	IF	CITATIONS
145	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. Blood, 2008, 112, 1733-1733.	1.4	3
146	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. Blood, 2008, 112, 869-869.	1.4	6
147	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 2006, 107, 1227-1229.	1.4	113
148	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology, 2006, 134, 417-425.	2.5	84
149	Drug Insight: emerging therapies for amyloidosis. Nature Clinical Practice Nephrology, 2006, 2, 263-270.	2.0	33
150	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. Blood, 2006, 108, 129-129.	1.4	11
151	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. Blood, 2005, 106, 3495-3495.	1.4	2
152	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. Immunology, 2004, 112, 255-264.	4.4	63
153	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. New England Journal of Medicine, 2002, 346, 1786-1791.	27.0	621